Pine Brook, NJ (PRWEB) December 12, 2013
Doctors Farrell Tyson, MD and Mark Latina, MD led two important discussions on office-based electrophysiology at this year’s American Academy of Ophthalmology Meeting (AAO) in New Orleans. Attendees crowded into the meeting rooms to learn about the clinical and financial benefits of integrating the Diopsys® NOVA-VEP and NOVA-ERG Vision Testing System into their practice.
The first presentation, “VEP/ERG for the Office: How New Technology is Improving Patient Care and Practice Revenue” was given by Dr. Tyson where he reviewed his personal experience integrating electrophysiology into his practice flow. He spoke about how important it was to have a technology that objectively assessed the function of the patient’s vision system, not just the structure of the eye. “We’re measuring the optical pathway which really allows us now to look at different aspects in our glaucoma and retina patients that we haven’t looked at before. Usually we are asking, ‘What is the level of destruction to cells? What is the pathology that we can visualize?’ Now we’re actually able to see pathology that hasn’t already destroyed cells but is traumatizing the ocular pathways.”
Dr. Latina led the second discussion, “Early Detection of Glaucoma and Other Maculopathies using New Office Based VEP and ERG.” He spoke about the values electrophysiology can bring to diagnosing glaucoma, macular degeneration and a host of other vision disorders. Early in his presentation, he spoke about the technology being used in an office setting. “VEP and ERG have important implications for how we’re practicing medicine. It may be a new technology for us as clinicians, but it’s really an old technology which I think is important because there’s been a lot of research done on it over the years.” This research can help guide doctors on how electrophysiology can help improve their diagnostic capabilities.
The Diopsys® NOVA-VEP Vision Testing System objectively measures the functional responses of the entire visual pathway from the anterior segment of the eye to the visual cortex, while the Diopsys® NOVA-ERG helps doctors gain objective, functional information about the performance of the inner retinal cells of the eye. These tests are designed to provide data to the doctor to help detect cellular dysfunction that can precede evident structural defects, thereby contributing to earlier detection for more specific and timely management of vision disorders.
To learn more about VEP and pattern ERG testing, visit Diopsys.com or request information.
Diopsys, Inc. (http://www.diopsys.com/) is a medical instrumentation company dedicated to delivering high-quality, cost-effective preventative health care solutions. The company specializes in the development and marketing of patient-friendly, non-invasive vision testing devices utilizing electrophysiology, including Visual Evoked Potential and pattern Electroretinography.
Diopsys has developed and markets the patented Diopsys® NOVA-VEP and Diopsys® NOVA-ERG Vision Testing Systems utilized by optometrists and ophthalmologists to help in the detection, diagnosis and treatment of vision disorders, including glaucoma and macular degeneration. Diopsys also provides the Enfant® Pediatric VEP Vision Testing System, a device used in testing for visual deficits, including amblyopia, in children as young as six months of age.